Dabrafenib plus trametinib,
does it really help with Prevention of relapse and distant metastasis after complete resection of stage III BRAF V600-mutated melanoma?
research showsTwelve months of adjuvant dabrafenib plus trametinib is rated B because the placebo-controlled phase 3 COMBI-AD trial produced durable reductions in relapse and distant metastasis after complete resection of BRAF V600-mutated stage III melanoma. Among 870 participants, the final hazard ratio was 0.52 for relapse or death and 0.56 for distant metastasis or death. At nearly ten years, the overall-survival hazard ratio was 0.80, but the 95% confidence interval was 0.62 to 1.01 and P was 0.06, so an overall-survival benefit was not established and the grade is capped at B.
ads claimAdjuvant targeted therapy can be presented as a guarantee of cure after surgery or as proven survival extension for all melanoma. Direct evidence is limited to completely resected stage III cutaneous melanoma with a BRAF V600E or V600K mutation.
Useful facts when choosing a product
- Dabrafenib inhibits BRAF and trametinib inhibits MEK, blocking two points in the MAPK pathway as a prescription combination.
- The COMBI-AD adjuvant regimen used dabrafenib 150 mg twice daily plus trametinib 2 mg once daily for 12 months.
- Direct trial eligibility required completely resected stage IIIA, IIIB, or IIIC cutaneous melanoma with a confirmed BRAF V600E or V600K mutation.
- Pyrexia, chills, fatigue, nausea, skin reactions, and elevated liver enzymes can occur, and fever is a common reason for treatment interruption or dose modification.
What the research actually shows
Long and colleagues randomized 870 patients with completely resected stage IIIA through IIIC cutaneous melanoma carrying a BRAF V600E or V600K mutation to 12 months of combination therapy or double placebo under masking. In 2017, three-year relapse-free survival was 58% versus 39%. Final analysis retained a hazard ratio of 0.52 for relapse or death and 0.56 for distant metastasis or death, while overall survival favored treatment numerically but was not significant at a hazard ratio of 0.80 and a 95% confidence interval of 0.62 to 1.01.
Why this is classified as B (77)
A placebo-controlled phase 3 trial and long follow-up show clear agent-specific reductions in relapse and distant metastasis. Final overall survival did not reach significance, with a hazard ratio of 0.80 and P=0.06, so the rule for relapse-free-survival benefit without established overall survival yields B with 77 points.
Counterpoint. This verdict concerns BRAF and MEK targeted therapy in BRAF V600-mutated tumors, not immune-checkpoint adjuvant therapy.
Rejudgment record. New verdict — Applied the B ceiling because placebo-controlled phase 3 follow-up showed durable reductions in relapse and distant metastasis, while final overall-survival superiority was not statistically established
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of relapse after complete resection of stage III BRAF V600-mutated melanoma | B | The final hazard ratio for relapse or death was 0.52, showing durable benefit. |
| Prevention of distant metastasis after complete resection of stage III BRAF V600-mutated melanoma | B | The final hazard ratio for distant metastasis or death was 0.56. |
| Longer overall survival after complete resection of stage III BRAF V600-mutated melanoma | C | The final hazard ratio was 0.80 with a 95% confidence interval of 0.62 to 1.01 and P=0.06, so superiority was not established in the overall population. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Long GV et al. COMBI-AD, 2017 | Multicenter randomized double-blind double-placebo-controlled phase 3 trial | 870 | GlaxoSmithKline and Novartis | Relapse-free survival, overall survival, and distant-metastasis-free survival | The combination was superior, with three-year relapse-free survival of 58% versus 39% and a hazard ratio of 0.47 for relapse or death. | Pivotal relapse-prevention trial |
| Long GV et al. COMBI-AD final analysis, 2024 | Near-ten-year final follow-up of the same randomized trial | 870 | GlaxoSmithKline and Novartis | Overall survival, relapse-free survival, and distant-metastasis-free survival | Hazard ratios were 0.52 for relapse or death and 0.56 for distant metastasis or death, while the overall-survival hazard ratio of 0.80 was not significant. | Long-term durability and overall-survival limitation |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Dabrafenib plus trametinib x relapse prevention in resected stage III BRAF-mutated melanoma — Evidence Grade B·77. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/dabrafenib-trametinib-adjuvant-stage-iii-braf-melanoma/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.